• Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., Ronneberger, O., Willmore, L., Ballard, A.J., Bambrick, J., et al., 2024. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature, 630, 493-500.

  • Al Qaraghuli, M.M.,Ferro, V.A., 2016. Analysis of the binding loops configuration and surface adaptation of different crystallized single-domain antibodies in response to various antigens. Journal of Molecular Recognition, 30, 1-12.

  • Borisevich, V., Lee, B., Hickey, A., Debuysscher, B., Broder, C.C., Feldmann, H.,Rockx, B., 2016. Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo. Journal of Infectious Diseases, 213, 448-455.

  • Chen, L., Sun, M., Zhang, H., Zhang, X., Yao, Y., Li, M., Li, K., Fan, P., Zhang, H., Qin, Y., Zhang, Z., Li, E., Chen, Z., Guan, W., Li, S., Yu, C., Zhang, K., Gong, R.,Chiu, S., 2024. Potent human neutralizing antibodies against Nipah virus derived from two ancestral antibody heavy chains. Nature Communications, 15, 2987.

  • Chen, X., Zaro, J.L.,Shen, W.C., 2013. Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev, 65, 1357-1369.

  • Chen, Y., Lin, X., Qin, Y., Wu, D., Gu, J.,Nie, S., 2023. Discovery of novel anti-serum albumin VHH as a building block for PK prolongation. Antibody Therapeutics, 6, tbad014.011.

  • Dang, H.V., Chan, Y.P., Park, Y.J., Snijder, J., Da Silva, S.C., Vu, B., Yan, L., Feng, Y.R., Rockx, B., Geisbert, T.W., Mire, C.E., Broder, C.C.,Veesler, D., 2019. An antibody against the F glycoprotein inhibits Nipah and Hendra virus infections. Nat Struct Mol Biol, 26, 980-987.

  • Dang, H.V., Cross, R.W., Borisevich, V., Bornholdt, Z.A., West, B.R., Chan, Y.P., Mire, C.E., Da Silva, S.C., Dimitrov, A.S., Yan, L., Amaya, M., Navaratnarajah, C.K., Zeitlin, L., Geisbert, T.W., Broder, C.C.,Veesler, D., 2021. Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins. Nat Struct Mol Biol, 28, 426-434.

  • De Genst, E., Silence, K., Decanniere, K., Conrath, K., Loris, R., Kinne, J., Muyldermans, S.,Wyns, L., 2006. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci U S A, 103, 4586-4591.

  • Donaldson, H.,Lucey, D., 2018. Enhancing preparation for large Nipah outbreaks beyond Bangladesh: Preventing a tragedy like Ebola in West Africa. Int J Infect Dis, 72, 69-72.

  • Dong, J., Cross, R.W., Doyle, M.P., Kose, N., Mousa, J.J., Annand, E.J., Borisevich, V., Agans, K.N., Sutton, R., Nargi, R., Majedi, M., Fenton, K.A., Reichard, W., Bombardi, R.G., Geisbert, T.W.,Crowe, J.E., Jr., 2020. Potent Henipavirus Neutralization by Antibodies Recognizing Diverse Sites on Hendra and Nipah Virus Receptor Binding Protein. Cell, 183, 1536-1550 e1517.

  • Doyle, M.P., Kose, N., Borisevich, V., Binshtein, E., Amaya, M., Nagel, M., Annand, E.J., Armstrong, E., Bombardi, R., Dong, J., Schey, K.L., Broder, C.C., Zeitlin, L., Kuang, E.A., Bornholdt, Z.A., West, B.R., Geisbert, T.W., Cross, R.W.,Crowe, J.E., Jr., 2021. Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein. Cell Rep, 36, 109628.

  • Dsouza, N., Gupta, D.B.,Chellasamy, S.K., 2023. Distinct Host Gene Targets and Mode of Action in the MicroRNA of Nipah Virus from Malaysia and Bangladesh: A Comparative in-silico Based Analysis. Biomedical and Biotechnology Research Journal (BBRJ), 7, 340-350.

  • Gurajala, S.,Gurajala, S.S., 2026. Nipah Virus in Focus: A Comprehensive Review of the Pathogenesis, Epidemiological Patterns, Diagnostic Advances, and Future Public Health Strategies. Cureus, 18, e103807.

  • Hanke, L., Das, H., Sheward, D.J., Perez Vidakovics, L., Urgard, E., Moliner-Morro, A., Kim, C., Karl, V., Pankow, A., Smith, N.L., Porebski, B., Fernandez-Capetillo, O., Sezgin, E., Pedersen, G.K., Coquet, J.M., Hallberg, B.M., Murrell, B.,Mcinerney, G.M., 2022. A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo. Nat Commun, 13, 155.

  • Hickey, A.C.,Broder, C.C., 2009. The mechanism of henipavirus fusion: Examining the relationships between the attachment and fusion glycoproteins. Virologica Sinica, 24, 110-120.

  • Hoefman, S., Ottevaere, I., Baumeister, J.,Sargentini-Maier, M., 2015. Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®. Antibodies, 4, 141-156.

  • Huang, K., Ying, T.,Wu, Y., 2022. Single-Domain Antibodies as Therapeutics for Respiratory RNA Virus Infections. Viruses, 14, 1162.

  • Isaacs, A., Nieto, G.V., Zhang, X., Modhiran, N., Barr, J., Thakur, N., Low, Y.S., Parry, R.H., Barnes, J.B., Jara, R., et al., 2025. A nanobody-based therapeutic targeting Nipah virus limits viral escape. Nat Struct Mol Biol, 10.1038/s41594-025-01598-2.

  • Khetawat, D.,Broder, C.C., 2010. A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system. Virol J, 7, 312.

  • Krissinel, E.,Henrick, K., 2007. Inference of macromolecular assemblies from crystalline state. J Mol Biol, 372, 774-797.

  • Loomis, R.J., Stewart-Jones, G.B.E., Tsybovsky, Y., Caringal, R.T., Morabito, K.M., Mclellan, J.S., Chamberlain, A.L., Nugent, S.T., Hutchinson, G.B., Kueltzo, L.A., Mascola, J.R.,Graham, B.S., 2020. Structure-Based Design of Nipah Virus Vaccines: A Generalizable Approach to Paramyxovirus Immunogen Development. Front Immunol, 11, 842.

  • Ma, J., Chen, R., Huang, W., Nie, J., Liu, Q., Wang, Y.,Yang, X., 2019. In vitro and in vivo efficacy of a Rift Valley fever virus vaccine based on pseudovirus. Hum Vaccin Immunother, 15, 2286-2294.

  • Madsen, A.V., Mejias-Gomez, O., Pedersen, L.E., Preben Morth, J., Kristensen, P., Jenkins, T.P.,Goletz, S., 2024. Structural trends in antibody-antigen binding interfaces: a computational analysis of 1833 experimentally determined 3D structures. Computational and Structural Biotechnology Journal, 23, 199-211.

  • Mallapaty, S., 2024. The pathogens that could spark the next pandemic. Nature, 632, 488.

  • Mannar, D., Saville, J.W., Zhu, X., Srivastava, S.S., Berezuk, A.M., Tuttle, K.S., Marquez, A.C., Sekirov, I.,Subramaniam, S., 2022. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science, 375, 760-764.

  • May, A.J.,Acharya, P., 2024. Structural Studies of Henipavirus Glycoproteins. Viruses, 16, 195.

  • Mima, M., Mishima-Tsumagari, C., Nakano, K., Morimoto, M., Ogata, H., Sakata, M., Iwaoka, R., Iwata, K., Hachiuma, K., Iwamoto, K., Fujii, Y.,Kurokawa, T., 2024. Structural design of the anti-TNFα therapeutic NANOBODY® compound, ozoralizumab, to support its potent and sustained clinical efficacy. Biochem Biophys Res Commun, 734, 150454.

  • Negrete, O.A., Levroney, E.L., Aguilar, H.C., Bertolotti-Ciarlet, A., Nazarian, R., Tajyar, S.,Lee, B., 2005. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature, 436, 401-405.

  • Nie, J., Liu, L., Wang, Q., Chen, R., Ning, T., Liu, Q., Huang, W.,Wang, Y., 2019. Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities. Emerg Microbes Infect, 8, 272-281.

  • Piccoli, L., Park, Y.J., Tortorici, M.A., Czudnochowski, N., Walls, A.C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L.E., Bowen, J.E., et al., 2020. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 183, 1024-1042.e1021.

  • Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.H., Porrot, F., Staropoli, I., Lemoine, F., et al., 2022. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature, 602, 671-675.

  • Playford, E.G., Munro, T., Mahler, S.M., Elliott, S., Gerometta, M., Hoger, K.L., Jones, M.L., Griffin, P., Lynch, K.D., Carroll, H., et al., 2020. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infect Dis, 20, 445-454.

  • Punjani, A., Rubinstein, J.L., Fleet, D.J.,Brubaker, M.A., 2017. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat Methods, 14, 290-296.

  • Swart, I.C., Van Gelder, W., De Haan, C.a.M., Bosch, B.J.,Oliveira, S., 2024. Next generation single-domain antibodies against respiratory zoonotic RNA viruses. Front Mol Biosci, 11, 1389548.

  • Takeuchi, T., 2023. Structural, nonclinical, and clinical features of ozoralizumab: A novel tumour necrosis factor inhibitor. Mod Rheumatol, 33, 1059-1067.

  • Terryn, S., Francart, A., Lamoral, S., Hultberg, A., Rommelaere, H., Wittelsberger, A., Callewaert, F., Stohr, T., Meerschaert, K., Ottevaere, I., Stortelers, C., Vanlandschoot, P., Kalai, M.,Van Gucht, S., 2014. Protective effect of different anti-rabies virus VHH constructs against rabies disease in mice. PLoS One, 9, e109367.

  • Vasudevan, S.S., Subash, A., Mehta, F., Kandrikar, T.Y., Desai, R., Khan, K., Khanduja, S., Pitliya, A., Raavi, L., Kanagala, S.G.,Gondaliya, P., 2024. Global and regional mortality statistics of nipah virus from 1994 to 2023: a comprehensive systematic review and meta-analysis. Pathogens and Global Health, 10.1080/20477724.2024.2380131, 1-10.

  • Wang, S., Rao, G., Zhang, X., Yao, Y., Chen, L., Chen, S., Zhang, H., Liu, H., Chen, M., Li, W., Cao, S., Chiu, S.,Gong, R., 2026. Highly potent C-type nanoantibodies neutralize Nipah and Hendra viruses by cavity filling on fusion glycoprotein. Nat Commun, 17, 6978.

  • Wang, Y., Sun, Y., Shen, Z., Wang, C., Qian, J., Mao, Q., Wang, Y., Song, W., Kong, Y., Zhan, C., Chen, Z., Dimitrov, D.S., Yang, Z., Jiang, S., Wu, F., Lu, L., Ying, T., Sun, L.,Wu, Y., 2024. Fully human single-domain antibody targeting a highly conserved cryptic epitope on the Nipah virus G protein. Nature Communications, 15, 6892.

  • Wang, Z., Amaya, M., Addetia, A., Dang, H.V., Reggiano, G., Yan, L., Hickey, A.C., Dimaio, F., Broder, C.C.,Veesler, D., 2022a. Architecture and antigenicity of the Nipah virus attachment glycoprotein. Science, 375, 1373-1378.

  • Wang, Z., Dang, H.V., Amaya, M., Xu, Y., Yin, R., Yan, L., Hickey, A.C., Annand, E.J., Horsburgh, B.A., Reid, P.A., Smith, I., Eden, J.S., Xu, K., Broder, C.C.,Veesler, D., 2022b. Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant. Proc Natl Acad Sci U S A, 119, e2122769119.

  • Whelan, S., Liu, Q., Stone, J.A., Bradel-Tretheway, B., Dabundo, J., Benavides Montano, J.A., Santos-Montanez, J., Biering, S.B., Nicola, A.V., Iorio, R.M., Lu, X.,Aguilar, H.C., 2013. Unraveling a Three-Step Spatiotemporal Mechanism of Triggering of Receptor-Induced Nipah Virus Fusion and Cell Entry. PLoS Pathogens, 9, e1003770.

  • WHO, 2026a. Nipah virus infection - Bangladesh. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON594.

  • WHO, 2026b. Nipah virus infection - India. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON593.

  • Xu, K., Chan, Y.P., Bradel-Tretheway, B., Akyol-Ataman, Z., Zhu, Y., Dutta, S., Yan, L., Feng, Y., Wang, L.F., Skiniotis, G., Lee, B., Zhou, Z.H., Broder, C.C., Aguilar, H.C.,Nikolov, D.B., 2015. Crystal Structure of the Pre-fusion Nipah Virus Fusion Glycoprotein Reveals a Novel Hexamer-of-Trimers Assembly. PLoS Pathog, 11, e1005322.

  • Xu, K., Rockx, B., Xie, Y., Debuysscher, B.L., Fusco, D.L., Zhu, Z., Chan, Y.P., Xu, Y., Luu, T., Cer, R.Z., Feldmann, H., Mokashi, V., Dimitrov, D.S., Bishop-Lilly, K.A., Broder, C.C.,Nikolov, D.B., 2013. Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody. PLoS Pathog, 9, e1003684.

  • Zhu, Z., Bossart, K.N., Bishop, K.A., Crameri, G., Dimitrov, A.S., Mceachern, J.A., Feng, Y., Middleton, D., Wang, L.F., Broder, C.C.,Dimitrov, D.S., 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis, 197, 846-853.